Search Results for “AI” – Page 13 – media

New Blood Test Aims to Improve Management of Multiple Sclerosis

Multiple Sclerosis (MS) is an autoimmune, inflammatory, and neurodegenerative condition where axonal loss leads to irreversible neurological damage and disability. Currently, approximately 2.8 million people globally are affected by MS, though this figure is likely underestimated due to underdiagnosis in underserved and remote areas lacking adequate neurological care and imaging facilities. While no cure exists for MS, available treatments aim to reduce the frequency of relapses, which are linked to nerve cell damage and the progression of the disease. There is a critical need for an accessible, affordable, and accurate blood test that can detect early signs of neuronal injury and disease activity. The neurofilament light chain (NfL) protein has been identified as a key biomarker for nerve cell damage. Now, a new blood test that measures levels of NfL could facilitate earlier detection of MS-related neuronal injury and improve disease management. Siemens Healthineers (Forchheim, Germany), in collaboration with Novartis ...
- Source: drugdu
- 88
- July 16, 2024
Indegene collaborates with Microsoft to promote use of GenAI in global life sciences companies

Indegene announced a strategic collaboration with Microsoft to empower global life sciences companies to scale up the adoption of purpose-built, enterprise-grade Generative AI services, thereby driving faster innovation at scale. Indegene and Microsoft have aimed to develop resources in highly specialised and skilled medical and technology tools to co-innovate generative AI services and workflows across commercial, medical, regulatory, and clinical functions. Some of the key use cases the strategic collaboration focuses on in the first phase, include: Content Super App: Using Azure OpenAI Service, the modular content value chain simplifies content creation and tagging for life sciences companies. This integrated approach offers a holistic view of the content value chain, enabling greater velocity, personalized content, and adoption of new conversation form factors. It also streamlines creative and video transformation while effectively engaging healthcare professionals (HCPs), patients and payers Future-ready medical content value chain: Generative AI capabilities are revolutionising the medical ...
- Source: drugdu
- 84
- July 13, 2024
Amylyx Aims to Help Patients With a Novel GLP-1 Drug, But Not the Way You Think

Unlike GLP-1 agonist drugs marketed for weight loss, new Amylyx Pharmaceuticals drug avexitide blocks its target receptor. Amylyx plans to advance this GLP-1 antagonist into Phase 3 testing for post-bariatric hypoglycemia, a rare condition in which blood sugar levels drop precipitously. By Frank VinluanBefore GLP-1 drugs became a wildly popular pharmacologic way to treat obesity, bariatric surgery was a top option for those seeking a medical intervention for losing weight. While this procedure is effective for weight loss, it turns out that changing the structure of the gut can lead to a debilitating disorder in some patients. Amylyx Pharmaceuticals, months removed from a clinical trial failure that shattered its prospects in neurodegeneration, is now planting a flag in metabolic disease with the acquisition of a Phase 3-ready drug for this rare disorder with no FDA-approved therapies. The drug comes from Eiger BioPharmaceuticals, which last month sold off its assets in ...
- Source: drugdu
- 73
- July 12, 2024
Francis Crick and ICL spinout raises £90m to clinically develop cancer treatments

The Francis Crick Institute and Imperial College London (ICL) cancer therapy spinout, Myricx Bio, has raised £90m in series A financing to advance its novel cancer treatments into clinical development. The investment will help to develop the company’s therapies to treat a range of different tumour types, including breast, lung and colorectal cancer, to advance into clinical testing. Currently the largest series A round to ever be raised by an EU academic biotech spinout, the round was co-led by life science investors Novo Holdings and Abingworth, with additional investors including British Patient Capital, Cancer Research Horizons and Eli Lilly and Company, as well as founding investors Brandon Capital and Sofinnova Partners. The spinout is focused on the discovery and development of a novel class of payloads for antibody-drug conjugates (ADCs), which involves antibodies that bind to the surface of certain tumour types to deliver a drug to its target. The ...
- Source: drugdu
- 57
- July 11, 2024
Chiatai Tianqing’s Bicalutamide Tablets Approved

On July 5, Chiatai Tianqing received the Certificate of Drug Registration issued by State Drug Administration, approving the company’s bicalutamide tablets for the treatment of advanced prostate cancer. This is the tenth product approved by Chiatai Tianqing this year. Prostate cancer is a common malignant tumor of the male reproductive system, and it is also the second most common malignant tumor in men worldwide, with the incidence rate on the rise globally. BCC Research’s latest report pointed out that the global prostate cancer treatment market reached $35.3 billion in 2022 and is expected to grow to $56.4 billion in 2028, with a compound annual growth rate of 8.3%. . As early symptoms of prostate cancer are not easy to be detected, most patients are found in the middle to late stages. The incidence of prostate cancer is high among middle-aged and elderly men, and with the growing proportion of elderly ...
- Source: drugdu
- 75
- July 10, 2024
New Lab Test Detects Persistent HIV Strains in Africa

Most research on the human immunodeficiency virus (HIV) has concentrated on the virus variants prevalent in Western nations, primarily impacting men who have sex with men, with a focus on subtype B. However, less attention has been given to the variants in Africa, where the virus significantly affects women. To develop a universally effective cure, it’s crucial to investigate viral variants not only in developed regions but across different global demographics. Researchers have now developed a test to measure HIV persistence in individuals predominantly affected by African viral strains—a critical step towards finding a cure that can aid patients globally. This research, published in Nature Communications on July 2, addresses a significant shortfall in HIV research. The findings of the study by a multinational team led by investigators at Weill Cornell Medicine (New York, NY, USA)—similar to findings in the developed world—revealed that African HIV strains form viral reservoirs in ...
- Source: drugdu
- 109
- July 5, 2024
Study finds headache drug could prevent overuse of acute migraine medications

Chronic migraine is a neurological condition estimated to affect up to 2.2% of people globally A study led by researchers at King’s College London (KCL) and funded by AbbVie has revealed that a headache drug helps to prevent the overuse of acute migraine medication. Published in Neurology, AbbVie’s Qulipta (atogepant) was shown to be effective in decreasing migraine days in adults living with chronic migraine. Estimated to affect up to 2.2% of the global population, chronic migraine is a debilitating neurological disease where people regularly experience at least 15 days a month of headaches. Most often, headaches can be intensified by the overuse of acute migraine medications such as triptans, ergots and simple analgesics, leading to worse pain relief outcomes over a 24-hour period. Funded by AbbVie, the study assessed the efficacy of Qulipta in preventing chronic migraine in patients who met the criteria for acute medicine overuse as well ...
- Source: drugdu
- 68
- July 5, 2024
Novel AI-Based Analysis Method Uncovers New Insight into ALS Progression

Amyotrophic Lateral Sclerosis (ALS) is a fatal condition where motor neurons, which are crucial for controlling movement, progressively die. Currently, there is no cure for ALS, and patients typically live between 2 and 5 years after diagnosis. Now, in a new study published in Science Advances, researchers have shown how to leverage artificial intelligence (AI) to gain deeper insights into ALS progression. The study, led by researchers from the School of Psychology and Neuroscience at the University of St Andrews (Scotland, UK), in collaboration with the Department of Neuroscience, University of Copenhagen (Copenhagen, Denmark), found that certain neural circuits that control movement are compromised early in the disease, while others deteriorate later as the disease progresses. The techniques used in the study allow for the simultaneous analysis of multiple cell types within the spinal cord, enhanced by an innovative AI-driven analytical method. This enabled the identification of specific networks of ...
- Source: drugdu
- 66
- July 4, 2024
Eli Lilly Alzheimer’s Drug Lands FDA Approval, Introducing Competition to Eisai’s Leqembi

Eli Lilly’s Kisunla is now FDA approved for treating patients in the early stages of Alzheimer’s disease. In addition to slowing cognitive decline and disease progression, clinical trial results showed that amyloid beta plaques were reduced to the point where some patients could stop taking the infused therapy. By Frank VinluanEli Lilly Alzheimer’s disease drug has received its long-awaited FDA approval, bringing patients a treatment that works similarly to an Eisai medication for the neurodegenerative disorder but with dosing advantages that patients might prefer. The Tuesday regulatory decision comes less than a month after an FDA advisory committee voted unanimously that the benefits of the Lilly drug in slowing cognitive decline outweigh its safety risks. The approval covers the treatment of Alzheimer’s patients with mild cognitive impairment or mild dementia, the same population that was evaluated in clinical trials. Known in development as donanemab, Lilly will market its new Alzheimer’s ...
- Source: drugdu
- 115
- July 4, 2024
Hengrui Pharmaceuticals Bupivacaine Liposome Injection Approved for Marketing in the United States

Today, Hengrui Pharmaceuticals Bupivacaine Liposome Injection was successfully approved for listing in the United States. This product is the first generic drug of this species approved for marketing in the world, and its listing in the U.S. is an important milestone in the international development of the company’s high-end preparations. Bupivacaine liposome injection was first approved in the United States in 2011, and the original product is currently sold only in the United States and Europe, and has not been imported domestically. Because of its high technical barriers, no generic product has been successfully listed for more than 10 years. Hengrui Pharmaceuticals Bupivacaine Liposome Injection has been approved to be listed in China at the end of 2022, which is the exclusive global first generic of Hengrui Pharmaceuticals’ Class 3 new drug, deemed to have passed the consistency evaluation, and is also the first ultra-long-acting local anesthesia drug in China, ...
- Source: drugdu
- 136
- July 4, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.